Skip to contentpdufa.bio

ATEBRIOZ (zilurgisertib): FDA NDA 221198

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 221198 is the FDA application for ATEBRIOZ (zilurgisertib). The FDA's Orange Book lists the applicant of record as MIRUM PHARMACEUTICALS INC and the first approval on it as Sep 25, 2026. Code name used in development: INCB000928. Owner today: Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 221198 · Orange Book NDA 221198

Names for this drug

Brand name (FDA)ATEBRIOZ
Orange Book trade name: ATEBRIOZ
Active ingredient (FDA)ZILURGISERTIB FUMARATE
Code nameINCB000928
Source: Incyte press release, May 25, 2023
“Phase 1/2 Study of the Activin Receptor-Like Kinase (ALK)-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104)”

Who holds the application

FDA applicant of recordMIRUM PHARMACEUTICALS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayMirum Pharmaceuticals, Inc. (MIRM)
Source: Mirum Pharmaceuticals and Incyte press release, Sep 25, 2026
“Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced”
Earlier / partnerIncyte (INCY): licensed the drug to the current owner
Source: Mirum Pharmaceuticals and Incyte press release, Sep 25, 2026
“Atebrioz was developed by Incyte and licensed to Mirum Pharmaceuticals, Inc. for worldwide development and commercialization.” … “Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced”

Products on NDA 221198 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001ATEBRIOZTABLET;ORALEQ 25MG BASESep 25, 2026

FDA decisions we track for this drug

Atebrioz (zilurgisertib)INCY · DecidedAtebrioz (zilurgisertib)MIRM · Decided

Drug page: /drug/atebrioz

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.